Skip to main content
Kuros Biosciences Ltd. logo

Kuros Biosciences Ltd. — Investor Relations & Filings

Ticker · KURN ISIN · CH0325814116 LEI · 5299006U5POB2AVTT709 SW Manufacturing
Open in API
Filings indexed 207 across all filing types
Latest filing 2024-06-25 Regulatory Filings
Country CH Switzerland
Listing SW KURN

About Kuros Biosciences Ltd.

https://kurosbio.com/

Kuros Biosciences is a life sciences company that discovers, develops, and delivers innovative biologic technologies focused on tissue repair and bone regeneration. The company's mission is to address unmet clinical needs for safer, faster, and more predictable bone healing. Its primary commercial product is MagnetOs, an advanced bone graft designed to enhance bone formation. The efficacy of MagnetOs is supported by a comprehensive global research program, "Project Fusion," which includes scientific, pre-clinical, and Level I human clinical studies. Kuros Biosciences serves surgeons and patients across multiple medical fields, including spine, extremities, trauma, and oncology, leveraging deep scientific expertise and collaboration with leading clinical experts.

Recent filings

Filing Released Lang Actions
Kuros Biosciences Announces Peer-Reviewed Publication of MagnetOs MAXA Level 1 Study Outcomes in Spine, Indicating Superiority Over Autograft
Regulatory Filings Classification · 98% confidence The document is a press release dated June 25, 2024, announcing the peer-reviewed publication of clinical study outcomes (MAXA Level 1 Study) for their product MagnetOs in the journal 'Spine'. It details scientific results, quotes researchers and the CEO, and provides context about the study and the product. This is not a formal regulatory filing like a 10-K or IR, nor is it a transcript (CT) or a formal dividend notice (DIV). It is an announcement of scientific/clinical data dissemination. While it contains financial context (CEO quote, CFO contact), its primary purpose is to disseminate research findings. This fits best under 'Regulatory Filings' (RNS) as a general corporate announcement, or potentially 'Investor Presentation' (IP) if it were a slide deck, but since it's a news release about a publication, RNS is the most appropriate general category for non-standard announcements, although it is highly specific scientific news. Given the options, RNS serves as the best fit for a general corporate news release about a scientific publication that doesn't fit the other specific categories like ER or MDA.
2024-06-25 English
Kuros Biosciences Announces Peer-Reviewed Publication of MagnetOs MAXA Level 1 Study Outcomes in Spine, Indicating Superiority Over Autograft
Investor Presentation Classification · 90% confidence The document is a press release from Kuros Biosciences AG announcing the publication of clinical study results for their product, MagnetOs, in the journal 'Spine'. It details scientific findings, compares them to the gold standard (autograft), and includes quotes from management and researchers. This type of announcement, focusing on scientific data dissemination and clinical trial outcomes, is best classified as an Investor Presentation (IP) or potentially a Regulatory Filing (RNS) if it were a mandatory disclosure. However, given the detailed scientific and clinical data presentation aimed at investors and the medical community, 'Investor Presentation' (IP) is the most fitting category among the provided options, as it functions as a detailed update on product efficacy and research progress, similar to what might be presented in an investor deck, even though it's formatted as a press release. It is not a formal regulatory report like a 10-K or IR, nor is it a general regulatory announcement (RNS) since it has a specific scientific focus. It is not an Earnings Release (ER) as it focuses on study results, not financial performance.
2024-06-25 English
Kuros reports Corporate Highlights as of Q1 2024 including increase in direct MagnetOsTM sales
Earnings Release Classification · 100% confidence The document is an 'Ad-hoc' announcement dated April 24, 2024, reporting 'Corporate Highlights as of Q1 2024'. It details financial performance (sales, EBITDA) and key operational updates (FDA clearance, management change) for the first quarter. This structure—a brief announcement summarizing key financial metrics for a recent period shorter than a year—is characteristic of an Earnings Release (ER). It is not the full, comprehensive report (which would be an IR), nor is it a transcript (CT) or a general regulatory filing (RNS). Since it provides the initial, high-level financial results for the quarter, 'ER' is the most appropriate classification. Q1 2024
2024-04-24 English
Kuros reports Corporate Highlights as of Q1 2024 including increase in direct MagnetOsTM sales
Earnings Release Classification · 100% confidence The document is titled 'Ad hoc announcement pursuant to Art. 53 LR' and explicitly states 'Release of an ad hoc announcement pursuant to Art. 53 LR'. It provides key financial highlights (Q1 2024 sales, EBITDA, cash position) and regulatory/commercial updates (FDA clearance, clinical study results, management change). This structure—a brief announcement summarizing key performance indicators and material events for a specific period (Q1 2024)—is characteristic of an Earnings Release (ER). Although it contains financial data, it is presented as a summary announcement rather than a comprehensive quarterly report (IR) or a full transcript (CT). Since it is an initial announcement of periodical financial results, ER is the most appropriate classification. Q1 2024
2024-04-24 English
Annual General Meeting of Kuros Biosciences approves all resolutions
AGM Information Classification · 99% confidence The document explicitly states that the company 'held its Annual General Meeting today' and details the resolutions approved, including the approval of the Annual Report, changes to the Board of Directors, and adjustments to the articles of association. The presence of keywords like 'Annual General Meeting', 'AGM', and the context of shareholder voting and board elections strongly indicates this is material related to the AGM. Therefore, the classification is AGM-R (AGM Information). The document length (4615 chars) is substantial enough to be the primary announcement/report of the meeting proceedings, not just a brief RPA.
2024-04-17 English
Annual General Meeting of Kuros Biosciences approves all resolutions
AGM Information Classification · 99% confidence The document explicitly states that the company 'held its Annual General Meeting today' and details the resolutions approved, including the approval of the Annual Report, election of board members, and adjustments to the articles of association. The key phrase is 'Annual General Meeting of Kuros Biosciences approves all resolutions'. This directly corresponds to the definition of AGM Information (AGM-R). Although it mentions approving the Annual Report, the primary focus and context of the release is the meeting itself.
2024-04-17 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.